Hepatitis C in liver transplant patients

Current Hepatitis Reports

Volumn 7, Issue 2, 2008, Pages 81-87

  Fink, Scott ^b   Gaglio, Paul J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; ERYTHROPOIETIN; GLUCOCORTICOID; INTERFERON; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; SEX HORMONE; STEROID; TACROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DONOR SELECTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FIBROSIS; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HEART DEATH; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FAILURE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAINTENANCE THERAPY; MIXED INFECTION; MONOTHERAPY; NECROINFLAMMATION; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PORTAL HYPERTENSION; PREOPERATIVE CARE; PROGNOSIS; RECURRENT DISEASE; REOPERATION; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VIRUS REPLICATION;

EID: 51949095071     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-008-0012-4     Document Type: Review

References (48)

1. Gane EJ, Portmann BC, Naoumov NV, et al.: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
2. Berenguer M, Ferrell L, Watson J, et al.: HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673-684.
3. Berenguer M, Prieto M, Rayon JM, et al.: Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852-858.
4. Forman LM, Lewis JD, Berlin JA, et al.: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
5. Kemmer N, Kaiser TE, Zacharias V, et al.: Revisiting posttransplant survival for hepatitis C virus recipients. Transplantation 2007, 84:932-933.
6. Cammà C, Di Bona D, Schepis F, et al.: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004, 39:333-340.
7. Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
8. Veldt BJ, Heathcote EJ, Wedemeyer H, et al.: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007, 147:677-684.
9. Iacobellis A, Siciliano M, Perri F, et al.: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206-212.
10. Weksler BR: Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007, 26:13-19.
11. Di Bisceglie AM, Shiffman ML, Everson GT, et al.: Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 2007, 46(Suppl 1):290A.
12. Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
13. Sherman M: Optimizing management strategies in special patient populations. Am J Gastroenterol 2006, 101(Suppl 1): S26-S31.
14. Lee LP, Dai CY, Chuang WL, et al.: Comparison of liver histopathology between chronic hepatitis C patietns and chronic hepatitis B and C-coinfected patients. J Gastroanterol Hepatol 2007, 22:515-517.
15. Cheruvu S, Marks K, Talal AH: Understandipg the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis 2007, 11:917-943.
16. Merchante N, Jiménez-Saenz M, Pineda JA: Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev 2007, 9:131-139.
17. McGovern BH: Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007, 45:S47-S45.
18. Bonacini M: Diagnosis and management of cirrhosis in coinfected patients. J Acquir Immune Defic Syndr 2007, 45: S38-S44.
19. Morra R, Munteanu M, Imbert-Bismut F, et al.: FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007, 7:481-489.
20. Halfon P, Bourliere M, Deydier R, et al.: Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006, 101:547-555.
21. Huwart L, Sempoux C, Salameh N, et al.: Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245:458-460.
22. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al.: Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007, 5:1214-1220.
23. Roche B, Samuel D: Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007, 14:89-96.
24. Cameron AM, Ghobrial RM, Hiatt JR, et al.: Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006, 244:563-571.
25. Onaca NN, Levy MF, Netto GJ, et al.: Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 2003, 3:626-630.
26. Briceño J, Ciria R, Pleguezuelo M, et al.: Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007, 39:2297-2299.
27. Botha JF, Thompson E, Gilroy R, et al.: Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007, 27:758-763.
28. Rayhill SC, Wu YM, Katz DA, et al.: Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007, 84:331-339.
29. Belli LS, Burroughs AK, Burra P, et al.: Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007, 13:733-740.
30. Gaglio PJ, Malireddy S, Levitt BS, et al.: Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003, 9:1028-1035.
31. Terrault NA, Shiffman ML, Lok AS, et al.: A2ALL Study Group: Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007, 13:122-129.
32. Lee KW, Simpkins CE, Montgomery RA, et al.: Factors affecting graft survival after liver transplantation from donation after cardiac death donors. Transplantation 2006, 82:1683-1688.
33. Dezza MC, Berrevoet F, Sainz-Barriga M, et al.: The choice of recipient does not have a bearing on early outcome in liver transplant patients receiving grafts from non-heartbeating donors: a reappraisal? Transplant Proc 2007, 39:2675-2677.
34. Katz LH, Mor E, Brown M, et al.: Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome. Clin Transplant 2006, 20:465-470.
35. Klintmalm GB, Washburn WK, Rudich SM, et al.: Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13:1521-1531.
36. Vivarelli M, Burra P, Barba GL, et al.: Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007, 47:793-798.
37. Berenguer M, Royuela A, Zamora J: Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007, 13:21-29.
38. Guitard J, Sandres-Sauné K, Kamar N: Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients. Transplant Proc 2007, 39:2603-2605.
39. Bahra M, Neumann UP, Jacob D, et al.: Repeated steroid pulse therapies in HCV-positive liver recipients. Transplant Proc 2005, 37:1700-1702.
40. Wiesner RH, Shorr JS, Steffen BJ, et al.: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005, 11:750-759.
41. Kwo PY, Saxena R, Cummings OW, et al.: Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus. Liver Transpl 2007, 13:1710-1713.
42. Arjal RR, Burton JR Jr, Villamil F, et al.: Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007, 26:127-140.
43. Wiesner RH, Sorrell M, Villamil F, et al.: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.
44. Saab S, Oh MK, Ibrahim AB, et al.: Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007, 13:1032-1038.
45. Schecter JM, Mears JG, Alobeid B, et al.: Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus. Liver Transpl 2007, 13:1589-1592.
46. Picciotto FP, Tritto G, Lanza AG, et al.: Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007, 46:459-465.
47. Kornberg A, Küpper B, Tannapfel A, et al.: Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study. J Gastroenterol Hepatol 2007, 22:2135-2142.
48. McCashland T, Watt K, Lyden E, et al.: Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007, 13:1246-1253.